Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov1695710.25208/vdv16957olfaqgREVIEWSОБЗОР ЛИТЕРАТУРЫReview ArticleTriterpenes in the pathogenetic therapy of cutaneous wounds associated with congenital epidermolysis bullosa: a review of current dataТритерпены в патогенетической терапии кожных ран при врожденном буллезном эпидермолизе: обзор актуальных данныхhttps://orcid.org/0000-0001-6079-2044BatpenovaGulnar R.БатпеноваГульнар Рыскельдыевна
Kazakhstan

MD, Dr. Sci. (Med.), Professor

д.м.н., профессор

gbatpenova@yandex.kzhttps://orcid.org/0009-0001-0855-8610MahmudovFaridМахмудовФарид
Azerbaijan

MD, Dr. Sci. (Med.), Professor

д.м.н., профессор

fmahmudov@amu.edu.azhttps://orcid.org/0000-0003-3988-0490RakhmatovAkram B.РахматовАкрам Баратович
Uzbekistan

MD, Dr. Sci. (Med.), Professor

д.м.н., профессор

rakhmatov1953@gmail.comhttps://orcid.org/0009-0002-7216-7427DjafarovaGulnaraДжафароваГюльнара
Azerbaijan
gulnarajafarova65@gmail.comhttps://orcid.org/0000-0003-2919-2838KhaldarbekovMadamin K.ХалдарбековМадамин Каримжанович
Uzbekistan

MD, Chief of the Genodermatoses Department

врач-дерматовенеролог, зав. отделением генодерматозов

madamin87@inbox.ruhttps://orcid.org/0000-0001-6981-2267TsoyNatalya O.ЦойНаталья Олеговна
Kazakhstan

MD, Cand. Sci. (Med.), Assistant Professor

к.м.н., доцент

tsoy_natasha@inbox.ruAstana Medical UniversityМедицинский университет АстанаAzerbaijan Medical UniversityАзербайджанский медицинский университетRepublican Specialized Scientific and Practical Medical Center of Dermatovenereology and CosmetologyРеспубликанский специализированный научно-практический медицинский центр дерматовенерологии и косметологииChildren’s Dermatovenereology Dispensary No. 1, BakuДетский кожно-венерологический диспансер № 1, Баку1706202602072026102224332001202613052026Copyright ©; 2026, Batpenova G.R., Mahmudov F., Rakhmatov A.B., Djafarova G., Khaldarbekov M.K., Tsoy N.O.Copyright ©; 2026, Батпенова Г.Р., Махмудов Ф., Рахматов А.Б., Джафарова Г., Халдарбеков М.К., Цой Н.О.2026Batpenova G.R., Mahmudov F., Rakhmatov A.B., Djafarova G., Khaldarbekov M.K., Tsoy N.O.Батпенова Г.Р., Махмудов Ф., Рахматов А.Б., Джафарова Г., Халдарбеков М.К., Цой Н.О.https://creativecommons.org/licenses/by-nc/4.0https://vestnikdv.ru/jour/article/view/16957

This review analyses the mechanism of action and clinical efficacy of a triterpene complex (birch bark extract), the first product for pathogenetic treatment of wounds associated with dystrophic and junctional congenital epidermolysis bullosa. Biologically active components of the triterpene complex affect key stages of the wound process by modulating the inflammatory phase, regulating cytokine and chemokine production, stimulating keratinocyte migration and differentiation, and promoting restoration of dermo-epidermal cohesion. These effects are aimed at correcting the impaired wound healing mechanisms typical for patients with congenital epidermolysis bullosa.

The clinical efficacy of the pathogenetic treatment has been demonstrated in the international, randomized, double-blind, phase III trial (EASE), in which the administration of the gel containing the triterpene complex resulted in statistically significant accelerated wound closure, reduced pain severity during dressing changes, and decreased frequency of dressing changes. A favourable safety profile and sustained clinical effect were confirmed in the 24-month open-label study phase as well as in the clinical observations in real-world settings.

Thus, the administration of the gel containing the triterpene complex is a pathogenetically justified approach to the treatment of chronic cutaneous wounds in patients with congenital epidermolysis bullosa.

Настоящий обзор анализирует механизм действия и клиническую эффективность комплекса тритерпенов (экстракт коры березы) — первого средства патогенетической терапии для лечения ран при дистрофическом и пограничном врожденном буллезном эпидермолизе. Биологически активные компоненты комплекса тритерпенов воздействуют на ключевые этапы раневого процесса: модулируют воспалительную фазу, регулируют продукцию цитокинов и хемокинов, стимулируют миграцию и дифференцировку кератиноцитов, а также способствуют восстановлению дермо-эпидермальной когезии. Эти эффекты направлены на коррекцию нарушенных механизмов заживления ран, характерных для пациентов с врожденным буллезным эпидермолизом.

Клиническая эффективность средства патогенетической терапии подтверждена результатами международного рандомизированного двойного слепого исследования III фазы (EASE), в котором применение геля, содержащего комплекс тритерпенов, сопровождалось достоверным ускорением закрытия ран, снижением интенсивности боли при перевязках и уменьшением частоты смены повязок. Благоприятный профиль безопасности и устойчивость клинического эффекта были подтверждены в 24-месячной открытой фазе исследования, а также в наблюдениях реальной клинической практики.

Таким образом, использование геля, содержащего комплекс тритерпенов, представляет собой обоснованный патогенетический подход к терапии хронических кожных ран у пациентов с врожденным буллезным эпидермолизом.

congenital epidermolysis bullosatriterpeneswound healingврожденный буллезный эпидермолизтритерпенызаживление ранThe publication was prepared with the support of Chiesi Pharmaceuticals LLC.Публикация подготовлена при поддержке ООО «Кьези Фармасьютикалс».El Hachem M, Diociaiuti A, Bonamonte D, et al. Taking care of patients with recessive dystrophic epidermolysis bullosa from birth to adulthood: a multidisciplinary Italian Delphi consensus. Orphanet J Rare Dis. 2025;20(1):128. doi: 10.1186/s13023-025-03635-1 EDN: HMTBKLПотекаев Н.Н., Жукова О.В., Поршина О.В., и др. Эпидемиология наследственного буллезного эпидермолиза в Российской Федерации. Клиническая дерматология и венерология. 2025;24(5):574–582. [Potekaev N, Zhukova O, Porshina O, et al. Epidemiology of inherited epidermolysis bullosa in the Russian Federation. Russian Journal of Clinical Dermatology and Venereology. 2025;24(5):574–582. (In Russ.)]. doi: 10.17116/klinderma202524051574 EDN: DIKSHFHas C, Bauer JW, Bodemer C, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol. 2020;183(4):614–627. doi: 10.1111/bjd.18921 EDN: VCZGJXFine JD. Epidemiology of inherited epidermolysis bullosa based on incidence and prevalence estimates from the national epidermolysis bullosa registry. JAMA Dermatol. 2016;152(11):1231–1238. doi: 10.1001/jamadermatol.2016.2473Petrof G, Papanikolaou M, Martinez AE, et al. The epidemiology of epidermolysis bullosa in England and Wales: data from the national epidermolysis bullosa database. Br J Dermatol. 2022;186(5):843–848. doi: 10.1111/bjd.20958 EDN: EFNBKVBodemer C, Soussand L, Sandrin A, et al. French data on the epidemiology and expert healthcare network for epidermolysis bullosa. J Eur Acad Dermatol Venereol. 2023;37(5):e597–e599. doi: 10.1111/jdv.18826Baardman R, Yenamandra VK, Duipmans JC, et al. Novel insights into the epidemiology of epidermolysis bullosa (EB) from the Dutch EB Registry: EB more common than previously assumed? J Eur Acad Dermatol Venereol. 2021;35(4):995–1006. doi: 10.1111/jdv.17012 EDN: WTWVZOHas C, Hess M, Anemüller W, et al. Epidemiology of inherited epidermolysis bullosa in Germany. J Eur Acad Dermatol Venereol. 2023;37(2):402–410. doi: 10.1111/jdv.18637 EDN: EDDUCCBardhan A, Bruckner-Tuderman L, Chapple ILC, et al. Epidermolysis bullosa. Nat Rev Dis Primers. 2020;6(1):78. doi: 10.1038/s41572-020-0210-0 EDN: DQISMITartaglia G, Cao Q, Padron ZM, South AP. Impaired wound healing, fibrosis, and cancer: the paradigm of recessive dystrophic epidermolysis bullosa. Int J Mol Sci. 2021;22(10):5104. doi: 10.3390/ijms22105104 EDN: BCGPTANyström A, Bruckner-Tuderman L, Kiritsi D. Dystrophic epidermolysis bullosa: secondary disease mechanisms and disease modifiers. Front Genet. 2021;12:737272. doi: 10.3389/fgene.2021.737272 EDN: PMKZRXTang JY, Marinkovich MP, Lucas E, et al. A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa. Orphanet J Rare Dis. 2021;16(1):175. doi: 10.1186/s13023-021-01811-7 EDN: ECLUSCBonamonte D, Filoni A, De Marco A, et al. Squamous cell carcinoma in patients with inherited epidermolysis bullosa: review of current literature. Cells. 2022;11(8):1365. doi: 10.3390/cells11081365 EDN: CDMYMDSchräder NHB, Korte EWH, Duipmans JC, et al. Identifying epidermolysis bullosa patient needs and perceived treatment benefits: an explorative study using the patient benefit index. J Clin Med. 2021;10(24):5836. doi: 10.3390/jcm10245836 EDN: KLGMQVChateau AV, Blackbeard D, Aldous C. The impact of epidermolysis bullosa on the family and healthcare practitioners: a scoping review. Int J Dermatol. 2023;62(4):459–475. doi: 10.1111/ijd.16197 EDN: KRTWPSBourrat E, Taieb C, Marquié A, et al. Burden of caregivers and out-of-pocket expenditures related to epidermolysis bullosa in France. J Eur Acad Dermatol Venereol. 2023;37(1):194–203. doi: 10.1111/jdv.18554 EDN: XFHTSSMellerio JE, Kiritsi D, Marinkovich MP, et al. Mapping the burden of severe forms of epidermolysis bullosa — Implications for patient management. JAAD Int. 2023;11:224–232. doi: 10.1016/j.jdin.2023.02.016 EDN: UVSCWUFilsuvez. In: European Medicines Agency [Internet]. Режим доступа: https://www.ema.europa.eu/en/medicines/human/EPAR/filsuvez Дата обращения: 20.06.2025.Drug Trials Snapshots: FILSUVEZ In: FDA. Режим доступа: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-filsuvez Дата обращения: 20.06.2025.Кубанов А.А., Карамова А.Э., Альбанова В.И., и др. Врожденный буллезный эпидермолиз: особенности регенерации эпидермиса и методы терапии. Вестник дерматологии и венерологии. 2017;93:28–37. [Kubanov АA, Karamova AE, Al’banova VI, et al. Congenital epidermolysis bullosa: peculiarities of epidermis regeneration and methods of treatment. Vestnik Dermatologii i Venerologii. 2017;93:28–37. (In Russ.)] doi: 10.25208/0042-4609-2017-93-4-28-37Efron PA, Moldawer LL. Cytokines and wound healing: the role of cytokine and anticytokine therapy in the repair response. J Burn Care Rehabil. 2004;25(2):149–160. doi: 10.1097/01.bcr.0000111766.97335.34Yoneda K, Furukawa T, Zheng YJ, et al. An autocrine/paracrine loop linking keratin 14 aggregates to tumor necrosis factor alpha-mediated cytotoxicity in a keratinocyte model of epidermolysis bullosa simplex. J Biol Chem. 2004;279(8):7296–7303. doi: 10.1074/jbc.M307242200Wally V, Lettner T, Peking P, et al. The pathogenetic role of IL-1β in severe epidermolysis bullosa simplex. J Invest Dermatol. 2013;133(7):1901–1903. doi: 10.1038/jid.2013.31Boniface K, Blom B, Liu YJ, et al. From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol Rev. 2008;226:132–146. doi: 10.1111/j.1600-065X.2008.00714.xHas C, Nyström A, Saeidian AH, et al. Epidermolysis bullosa: Molecular pathology of connective tissue components in the cutaneous basement membrane zone. Matrix Biol. 2018;71-72:313–329. doi: 10.1016/j.matbio.2018.04.001 EDN: YGQAFFWang Y, Hess ME, Tan Y, et al. Alterations in the microenvironment of junctional epidermolysis bullosa keratinocytes: A gene expression study. Matrix Biol. 2025;135:12–23. doi: 10.1016/j.matbio.2024.11.005 EDN: LZAMJNCañedo-Dorantes L, Cañedo-Ayala M. Skin acute wound healing: a comprehensive review. Int J Inflam. 2019;2019:3706315. doi: 10.1155/2019/3706315 EDN: NOGQWWHuitema L, Phillips T, Alexeev V, Igoucheva O. Immunological mechanisms underlying progression of chronic wounds in recessive dystrophic epidermolysis bullosa. Exp Dermatol. 2021;30(12):1724–1733. doi: 10.1111/exd.14411 EDN: SDXUWYLevin LE, Shayegan LH, Lucky AW, et al. Characterization of wound microbes in epidermolysis bullosa: Results from the epidermolysis bullosa clinical characterization and outcomes database. Pediatr Dermatol. 2021;38(1):119–124. doi: 10.1111/pde.14444 EDN: PQYWUBBrandling-Bennett HA, Morel KD. Common wound colonizers in patients with epidermolysis bullosa. Pediatr Dermatol. 2010;27(1):25–28. doi: 10.1111/j.1525-1470.2009.01070.xSinger HM, Levin LE, Garzon MC, et al. Wound culture isolated antibiograms and caregiver-reported skin care practices in children with epidermolysis bullosa. Pediatr Dermatol. 2018;35(1):92–96. doi: 10.1111/pde.13331Fine JD, Johnson LB, Weiner M, Suchindran C. Cause-specific risks of childhood death in inherited epidermolysis bullosa. J Pediatr. 2008;152(2):276–280. doi: 10.1016/j.jpeds.2007.06.039Rubin AI, Garzon MC, Morel KD. Herpetic infection in epidermolysis bullosa. Pediatr Dermatol. 2006;23(4):355–357. doi: 10.1111/j.1525-1470.2006.00254.xFine JD, Johnson LB, Weiner M, et al. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006. J Am Acad Dermatol. 2009;60(2):203–211. doi: 10.1016/j.jaad.2008.09.035Feinstein JA, Jambal P, Peoples K, et al. Assessment of the timing of milestone clinical events in patients with epidermolysis bullosa from North America. JAMA Dermatol. 2019;155(2):196–203. doi: 10.1001/jamadermatol.2018.4673Hoste E, Arwert EN, Lal R, et al. Innate sensing of microbial products promotes wound-induced skin cancer. Nat Commun. 2015;6:5932. doi: 10.1038/ncomms6932Fine JD, Johnson LB, Weiner M, Suchindran C. Assessment of mobility, activities and pain in different subtypes of epidermolysis bullosa. Clin Exp Dermatol. 2004;29(2):122–127. doi: 10.1111/j.1365-2230.2004.01428.x EDN: FMAOWJSnauwaert JJ, Yuen WY, Jonkman MF, et al. Burden of itch in epidermolysis bullosa. Br J Dermatol. 2014;171(1):73–78. doi: 10.1111/bjd.12885Danial C, Adeduntan R, Gorell ES, et al. Prevalence and characterization of pruritus in epidermolysis bullosa. Pediatr Dermatol. 2015;32(1):53–59. doi: 10.1111/pde.12391Mauritz P, Jonkman MF, Visser SS, et al. Impact of painful wound care in epidermolysis bullosa during childhood: an interview study with adult patients and parents. Acta Derm Venereol. 2019;99(9):783–788. doi: 10.2340/00015555-3179Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217–228.e13. doi: 10.1016/j.cell.2017.08.006Papanikolaou M, Onoufriadis A, Mellerio JE, et al. Prevalence, pathophysiology and management of itch in epidermolysis bullosa. Br J Dermatol. 2021;184(5):816–825. doi: 10.1111/bjd.19496 EDN: RYNTGIvan Scheppingen C, Lettinga AT, Duipmans JC, et al. Main problems experienced by children with epidermolysis bullosa: a qualitative study with semi-structured interviews. Acta Derm Venereol. 2008;88(2):143–150. doi: 10.2340/00015555-0376Alakurtti S, Mäkelä T, Koskimies S, Yli-Kauhaluoma J. Pharmacological properties of the ubiquitous natural product betulin. Eur J Pharm Sci. 2006;29(1):1–13. doi: 10.1016/j.ejps.2006.04.006 EDN: MFPEFXLaszczyk M, Jäger S, Simon-Haarhaus B, et al. Physical, chemical and pharmacological characterization of a new oleogel-forming triterpene extract from the outer bark of birch (betulae cortex). Planta Med. 2006;72(15):1389–1395. doi: 10.1055/s-2006-951723 EDN: MEYBOTSchwieger-Briel A, Ott H, Kiritsi D, et al. Mechanism of Oleogel-S10: A triterpene preparation for the treatment of epidermolysis bullosa. Dermatol Ther. 2019;32(4):e12983. doi: 10.1111/dth.12983Laszczyk MN. Pentacyclic triterpenes of the lupane, oleanane and ursane group as tools in cancer therapy. Planta Med. 2009;75(15):1549–1560. doi: 10.1055/s-0029-1186102Nistor G, Trandafirescu C, Prodea A, et al. Semisynthetic derivatives of pentacyclic triterpenes bearing heterocyclic moieties with therapeutic potential. Molecules. 2022;27(19):6552. doi: 10.3390/molecules27196552 EDN: ACBPUONoushahi HA, Khan AH, Noushahi UF, et al. Biosynthetic pathways of triterpenoids and strategies to improve their Biosynthetic Efficiency. Plant Growth Regul. 2022;97(3):439–454. doi: 10.1007/s10725-022-00818-9 EDN: RBKYGGGoddard ZR, Searcey M, Osbourn A. Advances in triterpene drug discovery. Trends Pharmacol Sci. 2024;45(11):964–968. doi: 10.1016/j.tips.2024.10.003 EDN: TFAJNYJ C Furtado NA, Pirson L, Edelberg H, et al. Pentacyclic triterpene bioavailability: an overview of in vitro and in vivo studies. Molecules. 2017;22(3):400. doi: 10.3390/molecules22030400Ebeling S, Naumann K, Pollok S, et al. From a traditional medicinal plant to a rational drug: understanding the clinically proven wound healing efficacy of birch bark extract. PLoS One. 2014;9(1):e86147. doi: 10.1371/journal.pone.0086147Woelfle U, Laszczyk MN, Kraus M, et al. Triterpenes promote keratinocyte differentiation in vitro, ex vivo and in vivo: a role for the transient receptor potential canonical (subtype) 6. J Invest Dermatol. 2010;130(1):113–123. doi: 10.1038/jid.2009.248CHMP. Filsuvez. Annex I. Summary of Product Characteristic n.d.Schwieger-Briel A, Kiritsi D, Schempp C, et al. Betulin-based oleogel to improve wound healing in dystrophic epidermolysis bullosa: a prospective controlled proof-of-concept study. Dermatol Res Pract. 2017;2017:5068969. doi: 10.1155/2017/5068969Kern JS, Sprecher E, Fernandez MF, et al. Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study. Br J Dermatol. 2023;188(1):12–21. doi: 10.1093/bjd/ljac001 EDN: RLOAAWBruckner AL, Murrell D, Lee LW, et al. Reduction in dressing change burden in patients with epidermolysis bullosa-impact of Oleogel-S10. J Dermatol. 2025;52(9):1447–1451. doi: 10.1111/1346-8138.17884 EDN: MWWUAZMurrell DF, Bodemer C, Bruckner AL, et al. Long-term safety and efficacy of Oleogel-S10 (birch bark extract) in epidermolysis bullosa: 24-month results from the phase III EASE study. Br J Dermatol. 2025;192(6):1007–1017. doi: 10.1093/bjd/ljaf022 EDN: GPCQSKTorres Pradilla M, Álvarez E, Novoa M, et al. Oleogel-S10 in dystrophic epidermolysis bullosa: a case series evaluating the impact on wound burden over two years. Adv Ther. 2024;41(2):867–877. doi: 10.1007/s12325-023-02749-x EDN: IISZMT